JP2017195888A5 - - Google Patents

Download PDF

Info

Publication number
JP2017195888A5
JP2017195888A5 JP2017106384A JP2017106384A JP2017195888A5 JP 2017195888 A5 JP2017195888 A5 JP 2017195888A5 JP 2017106384 A JP2017106384 A JP 2017106384A JP 2017106384 A JP2017106384 A JP 2017106384A JP 2017195888 A5 JP2017195888 A5 JP 2017195888A5
Authority
JP
Japan
Prior art keywords
nucleic acid
tumor
recombinant listeria
listeria strain
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017106384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017195888A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017195888A publication Critical patent/JP2017195888A/ja
Publication of JP2017195888A5 publication Critical patent/JP2017195888A5/ja
Pending legal-status Critical Current

Links

JP2017106384A 2008-05-19 2017-05-30 異種抗原のための二重送達システム Pending JP2017195888A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7179208P 2008-05-19 2008-05-19
US61/071,792 2008-05-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015067888A Division JP6182172B2 (ja) 2008-05-19 2015-03-30 異種抗原のための二重送達システム

Publications (2)

Publication Number Publication Date
JP2017195888A JP2017195888A (ja) 2017-11-02
JP2017195888A5 true JP2017195888A5 (OSRAM) 2017-12-14

Family

ID=41340826

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011510653A Active JP5757863B2 (ja) 2008-05-19 2009-05-19 異種抗原のための二重送達システム
JP2015067888A Active JP6182172B2 (ja) 2008-05-19 2015-03-30 異種抗原のための二重送達システム
JP2017106384A Pending JP2017195888A (ja) 2008-05-19 2017-05-30 異種抗原のための二重送達システム

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011510653A Active JP5757863B2 (ja) 2008-05-19 2009-05-19 異種抗原のための二重送達システム
JP2015067888A Active JP6182172B2 (ja) 2008-05-19 2015-03-30 異種抗原のための二重送達システム

Country Status (6)

Country Link
US (2) US20110129499A1 (OSRAM)
EP (2) EP2288379A4 (OSRAM)
JP (3) JP5757863B2 (OSRAM)
DK (1) DK2853269T3 (OSRAM)
ES (1) ES2741730T3 (OSRAM)
WO (1) WO2009143167A2 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20120135033A1 (en) * 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
JP5539411B2 (ja) * 2009-03-04 2014-07-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 血管新生因子を含む組成物およびその使用方法
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2498808A4 (en) * 2009-11-11 2014-01-08 Advaxis COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
EP2825195A4 (en) * 2012-03-12 2015-10-07 Advaxis Inc INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
MX2016010791A (es) 2014-02-18 2017-04-27 Advaxis Inc Inmunoterapia con multiples objetivos dirigida por biomarcadores.
MA39849A (fr) 2014-04-24 2017-03-01 Advaxis Inc Souches de listeria utilisées comme vaccin recombinant et procédé de production
SG11201700092XA (en) * 2014-07-18 2017-02-27 Advaxis Inc Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof
MX2017000857A (es) 2014-07-18 2017-10-11 Advaxis Inc Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata.
MA41644A (fr) * 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
US20180305702A1 (en) * 2015-09-15 2018-10-25 Advaxis, Inc. Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment
JP2018530588A (ja) * 2015-10-14 2018-10-18 アドバクシス， インコーポレイテッド 組み換え型リステリアワクチン株およびガン免疫療法におけるその使用方法
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
MX2019005685A (es) 2016-11-30 2019-09-04 Advaxis Inc Composiciones inmunogenicas contra mutaciones de cancer recurrentes y metodos de uso de las mismas.
KR102748132B1 (ko) 2017-09-19 2025-01-02 어드박시스, 인크. 박테리아 또는 리스테리아 균주의 동결건조를 위한 조성물 및 방법
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
CN111349645B (zh) * 2018-12-24 2022-05-17 上海若泰医药科技有限公司 一种提高非整合减毒李斯特菌疫苗安全性的方法

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1156953A (en) 1979-06-08 1983-11-15 Michael A. Kessick Lime addition to heavy crude oils prior to coking
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5262177A (en) 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
FR2686896B1 (fr) 1992-01-31 1995-01-06 Pasteur Institut Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5681570A (en) 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US6017705A (en) 1995-03-14 2000-01-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
CA2223103A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
WO1996040947A1 (en) 1995-06-07 1996-12-19 Washington University Recombinant bacterial system with environmentally limited viability
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
US5922583A (en) * 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
DE19541450C2 (de) 1995-11-07 1997-10-02 Gsf Forschungszentrum Umwelt Genkonstrukt und dessen Verwendung
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6740506B2 (en) * 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US5858682A (en) 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
CA2266656A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
KR20050084536A (ko) * 1997-04-17 2005-08-26 세키스이가가쿠 고교가부시키가이샤 도전성 미립자의 제조장치, 그 제조장치를 이용한 도전성미립자의 제조방법, 그 제조장치를 이용하여 이루어지는전자회로부품
CA2286210A1 (en) 1997-04-18 1998-10-29 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Attenuated salmonella strain used as a vehicle for oral immunization
WO1999007861A1 (en) 1997-08-06 1999-02-18 Laboratório Medinfar-Produtos Farmacêuticos, Lda. DNA INTEGRATION INTO 'MYCOBACTERIUM spp.' GENOME BY TRANS-COMPLEMENTATION USING A SITE-SPECIFIC INTEGRATION SYSTEM
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US20040013685A1 (en) 1997-11-10 2004-01-22 Peter Andersen Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
WO2000049158A2 (en) 1999-02-18 2000-08-24 Compugen Ltd. Psa and klk-2 splicing variants
DE60021760T2 (de) 1999-12-09 2006-06-08 Chiron Corp., Emeryville Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
JP2004500405A (ja) 2000-03-29 2004-01-08 ザ　トラスティーズ　オブ　ザ　ユニバーシティー　オブ　ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
WO2001079274A2 (en) 2000-04-19 2001-10-25 Statens Serum Institut Tuberculosis antigens and methods of use thereof
DE60120712T2 (de) 2000-08-11 2007-07-19 Mount Sinai Hospital, Toronto Kallikrein gen
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
FR2825633B1 (fr) 2001-06-11 2005-12-16 Bio Veto Tests Bvt Complexe vaccinal therapeutique destine a la prevention et au traitement des leishmanioses et des infections a microorganismes pathogenes intracellulaires chez le mammifere
US20060051380A1 (en) 2002-02-06 2006-03-09 The Johns Hopkins University Methods and compositions for the targeting of a systemic immune response to specific organs or tissues
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
JP2005527240A (ja) 2002-05-29 2005-09-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 弱毒リステリア種とこれを使用する方法
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20050175625A1 (en) 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
EP1408048A1 (en) 2002-10-07 2004-04-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
CA2512812A1 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
PT1592441E (pt) 2003-02-06 2012-05-21 Aduro Biotech Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
DE10310261A1 (de) 2003-03-05 2004-09-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Identifizierung von Antigen-Epitopen
JP2007509067A (ja) 2003-10-15 2007-04-12 メディミューン，インコーポレーテッド リステリアに基づくＥｐｈＡ２ワクチン
US7556814B2 (en) 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
WO2005061534A2 (en) 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
EP1708741B1 (en) 2003-12-24 2016-03-30 Aduro Biotech Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7858097B2 (en) 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
US7855064B2 (en) * 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
ES2684749T3 (es) * 2004-08-13 2018-10-04 The Trustees Of The University Of Pennsylvania Métodos para construir vacunas sin resistencia a antibióticos
AU2005295158A1 (en) 2004-10-18 2006-04-27 Medimmune, Llc High cell density process for growth of Listeria
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
CN100424096C (zh) 2005-06-16 2008-10-08 华东理工大学 含有hiv转导结构域的生存素突变体及制备方法和应用
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
WO2007061848A2 (en) 2005-11-17 2007-05-31 The Trustees Of The University Of Pennsylvania Methods for producing, growing, and preserving listeria vaccine vectors
RU2006112025A (ru) * 2005-12-16 2007-10-27 Хелт Рисерч Инк. (Us) Пептиды для стимуляции иммунного ответа против меланомы
EP1991263B8 (en) * 2006-03-01 2015-02-25 Aduro Biotech Engineered listeria and methods of use thereof
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
DK2046951T5 (da) 2006-07-05 2012-01-23 Catalyst Biosciences Inc Proteasesreeningsmetoder og proteaser identificeret dermed
US20080124354A1 (en) 2006-07-10 2008-05-29 Yvonne Paterson Methods for administering tumor vaccines
US8926993B2 (en) 2006-07-17 2015-01-06 Aduro Biotech Methods and compositions using Listeria for enhancing immunogenicity by prime boost
WO2008019131A2 (en) 2006-08-04 2008-02-14 The Trustees Of The University Of Pennsylvania Methods and compositions for treating ige-mediated diseases
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
WO2008130551A2 (en) * 2007-04-16 2008-10-30 The Trustees Of The University Of Pennsylvania Antibiotic resistance free listeria strains and methods for constructing and using same
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
WO2009110950A1 (en) 2007-12-31 2009-09-11 The Trustees Of The University Of Pennsylvania Attenuated listeria strain and adenovirus strain vaccines and methods of use
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
CN102076843A (zh) 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US20120135033A1 (en) 2008-05-19 2012-05-31 Anu Wallecha Multiple delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
CA2735006A1 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2498808A4 (en) 2009-11-11 2014-01-08 Advaxis COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US20110223187A1 (en) 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
SG10201700916SA (en) 2012-12-27 2017-03-30 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Similar Documents

Publication Publication Date Title
JP2017195888A5 (OSRAM)
JP2016156828A5 (OSRAM)
JP2017513502A5 (OSRAM)
JP2017507943A5 (OSRAM)
Tiptiri-Kourpeti et al. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy
JP2013526837A5 (OSRAM)
JP2018508212A5 (OSRAM)
RU2016137834A (ru) КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu
JP2017507918A (ja) Ｈｐｖおよび関連する疾病のための免疫増強治療ワクチン
CN118576699A (zh) Hbv疫苗
JP2017525336A5 (OSRAM)
JP2015096070A5 (OSRAM)
WO2007106476A2 (en) Compositions and methods for enhancing the immunogenicity of antigens
MX2022007902A (es) Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.
WO2009002418A3 (en) T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof
JP2020528911A5 (OSRAM)
WO2019094607A3 (en) Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
MA40228A (fr) Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser
WO2005028505A3 (en) Multiepitope polypeptides for cancer immunotherapy
EP4599845A3 (en) Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP2015506705A5 (OSRAM)
JP2018536002A5 (OSRAM)
EP4357356A3 (en) Antigenic peptides for prevention and treatment of b-cell malignancy
JP2018521651A5 (OSRAM)
RU2018123307A (ru) Вакцинация с использованием альфа3 домена mica/b для лечения рака